1. Home
  2. SPRO vs GSIT Comparison

SPRO vs GSIT Comparison

Compare SPRO & GSIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • GSIT
  • Stock Information
  • Founded
  • SPRO 2013
  • GSIT 1995
  • Country
  • SPRO United States
  • GSIT United States
  • Employees
  • SPRO N/A
  • GSIT N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • GSIT Semiconductors
  • Sector
  • SPRO Health Care
  • GSIT Technology
  • Exchange
  • SPRO Nasdaq
  • GSIT Nasdaq
  • Market Cap
  • SPRO 62.7M
  • GSIT 67.4M
  • IPO Year
  • SPRO 2017
  • GSIT N/A
  • Fundamental
  • Price
  • SPRO $1.17
  • GSIT $3.19
  • Analyst Decision
  • SPRO Buy
  • GSIT
  • Analyst Count
  • SPRO 3
  • GSIT 0
  • Target Price
  • SPRO $5.00
  • GSIT N/A
  • AVG Volume (30 Days)
  • SPRO 470.6K
  • GSIT 166.4K
  • Earning Date
  • SPRO 11-14-2024
  • GSIT 10-24-2024
  • Dividend Yield
  • SPRO N/A
  • GSIT N/A
  • EPS Growth
  • SPRO N/A
  • GSIT N/A
  • EPS
  • SPRO 0.06
  • GSIT N/A
  • Revenue
  • SPRO $106,455,000.00
  • GSIT $19,691,000.00
  • Revenue This Year
  • SPRO N/A
  • GSIT N/A
  • Revenue Next Year
  • SPRO N/A
  • GSIT N/A
  • P/E Ratio
  • SPRO $17.92
  • GSIT N/A
  • Revenue Growth
  • SPRO 37.01
  • GSIT N/A
  • 52 Week Low
  • SPRO $1.01
  • GSIT $1.88
  • 52 Week High
  • SPRO $1.89
  • GSIT $6.02
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 41.49
  • GSIT 54.30
  • Support Level
  • SPRO $1.28
  • GSIT $2.45
  • Resistance Level
  • SPRO $1.22
  • GSIT $3.20
  • Average True Range (ATR)
  • SPRO 0.07
  • GSIT 0.19
  • MACD
  • SPRO -0.01
  • GSIT 0.01
  • Stochastic Oscillator
  • SPRO 32.73
  • GSIT 88.10

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About GSIT GSI Technology

GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.

Share on Social Networks: